ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS

Bilen, Sule; Oztekin, Nese; KILINCKAYA, Muhammed Fevzi; Mühürdaroğlu, Mehmet; eruyar, esra

ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS

Mehmet MÜHÜRDAROĞLU, (Şereflikoçhisar Devlet Hastanesi, Ankara, Türkiye)

Esra ERUYAR, (Lokman Hekim Hastanesi, Ankara, Türkiye)

Muhammed Fevzi KILINCKAYA, (Mardin Halk Sağlığı Laboratuvarı, Mardin, Türkiye)

Sule Bilen, (Ankara Şehir Hastanesi, Nöroloji Kliniği, Ankara, Türkiye)

Zeynep Neşe ÖZTEKİN (Ankara Şehir Hastanesi, Nöroloji Kliniği, Ankara, Türkiye)

İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi

9 4

Yıl: 2023 Cilt: 27 Sayı: 2 Sayfa Aralığı: 158 - 164 Metin Dili: İngilizce İndeks Tarihi: 06-06-2023

ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS

Öz:

Introduction: Fetuin-A is a glycoprotein found to be elevated in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS). Examination of fetuin-A in MS may contribute to the our understanding of MS pathophysiology. We aimed to examine CSF and serum levels of fetuin-A in MS patients, and to assess relationships with disease activity. Materials and Methods: Twenty-two patients, classified as definite MS (n = 15) and clinically isolated syndrome (CIS, n = 7), and 27 age- and sex-matched cases with pseudotumor cerebri were included in the study. The ELISA method was used to determine fetuin-A levels in the CSF samples of the patient and control groups. Results: The patient and control groups were similar in terms of sex distribution, but mean age was significantly lower in patients (31.5 vs. 39.3 years, p>0.05).While patients and controls had similar fetuin-A levels at baseline and on the 6th month, CSF fetuin-A levels were significantly higher in patients with MS (p=0.01) compared to those with CIS.Patients with active and inactive disease had similar fetuin-A levelsin all comparisons, but patients with active disease appeared to have some what higher fetuin-A compared to those with inactive disease. Conclusion: To conclude, our findings showed that patients with MS and controls had similar fetuin-A levels (serum and CSF). However, at baseline, patients with MS had significantly higher fetuin-A concentrations compared to those with CIS. Fetuin-A levels were not si gnificantly associated with disease activity, but patients with active disease seemed to have relatively higher levels than those with inactive disease.

Anahtar Kelime:

MULTİPL SKLEROZDA HASTALIK AKTİVİTESİNİN FETUİN A DÜZEYLERİ İLE DEĞERLENDİRİLMESİ

Öz:

Giriş: Fetuin-A, multipl skleroz (MS) hastalarında beyin omurilik sıvısında (BOS) yükseldiği belirlenen bir glikoproteindir. MS olgularında Fetuin-A düzeyinin incelenmesi hastalığın etyopatogenizinin belirlenmesine katkı sağlayabilir. Bu çalışmada MS olgularında fetuin-A'nın BOS ve serum düzeylerini incelenmesi amaçlandı. Gereç ve Yöntem: Kesin MS(n = 15) ve klinik izole sendrom (KİS, n = 7) olarak sınıflandırılan 22 hasta ile yaş ve cinsiyet aç ısından e şleştirilmiş olan 27 pseudotumor serebri olgusu çalışmaya dahil edildi. Hasta ve kontrol grubunun BOS örneklerinde fetuin-A düzeylerini belirlemek için ELISA yöntemi kullanıldı. Bulgular: Hasta ve kontrol grupları cinsiyet da ğılımı açısından benzerdi; ancak ortalama yaş hasta grubunda daha dü şüktü(31,5 ve 39,3, p>0,05).Başlangıçta ve 6. ayda hastalar ve kontroller benzer fetuin-A seviyelerine sahipken, MS hastalarında BOS fetuin-A seviyeleri CIS hastalarına göre anlamlı olarak yüksekti (p=0,01). Bütün karşılaştırmalarda, aktif hastalığı olanlar ve inaktif hastalığı olanlar benzer fetuin-A seviyelerine sahipti; ancak, inaktif hastalarla kıyaslandığında aktif hastaların nispeten daha yüksek fetuin-A'ya düzeylerine sahip olduğu görüldü. Sonuç: Bulgularımız, MS'li hastaların ve kontrollerin fetuin-A düzeylerinin (serum ve BOS) benzer olduğunu gösterdi. Bununla birlikte, MS'li hastalar, CIS'li hastalara k ıyasla anlamlı ölçüde daha yüksek fetuin-A konsantrasyonlarına sahipti. Fetuin-A seviyeleri hastalık aktivitesi ile istatistiksel olarak ili şkili değildi, ancak inaktif hastalığa kıyasla aktif hastalıkta nispeten daha yüksek seviyeler tespit edildi.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Allen I, Brankin B. Pathogenesis of multiple sclerosis the immunediathesis and the role of vi ruses.J Neuropathol Exp Neurol 1993; 52(2):95-102.
2. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis. 2005 revisions to the “Mc Donald Criteria”. Ann Neurol 2005; 58(6): 840-6.
3. Bielekova B, Martin R.Development of biomarkers in multiple sclerosis. Brain 2004; 127: 1463-78.
4. Miller DH, Barkhoff F, Montalban X, Thomson A. Clinically isolated syndromes suggestive of multiple sclerosis Part I: Natural history, pathogenesis, diagnosis and prognosis, Lancet Neurology 2005;4(5):281-8.
5. Mori K, Emoto M, Inaba M.Fetuin-A: A multifunctional protein, Recent Pat Endocr Metab Immune Drug Discov 2011; 5: 124– 46.
6. Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B et al. Multiple sclerosis: identification and clinical evaluation of novel CSFbiomarkers. J Proteomics 2010;73(6):1117-32.
7. Harris VK, Donelan N, Yan QJ, Clark K, Touray A, Rammal M et al.Cerebrospinal fluid fetuin -A is a biomarker of active multiple sclerosis,. Mult Scler 2013; 19(11): 1462–72.
8. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnk en AH, Böhm R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet Neurology 2003;361 (9360):827-33.
9. Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y. Effect of phosphorylated rat fetuin on the growth ofhepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylatedfetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem 1997; 243(3): 753-61.
10. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S et al. Fetuin-A acts as an endogenousligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012; 18(8):1279-85.
11. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polm an CH et al.Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120 (Pt 11):2059–69.
12. Brettschneider, A. Petzold, A. Junker , H. Tumani. Axonal damage markers in t he cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.Mult Scle 2006; 12(2):143–8.
13. Tumani H, Lehmensiek V, Rau D, Guttmann I, Tauscher G, Mo gel H et al. CSF proteome analysis in clinically isolated syndrome (CIS): Candidate markers for conversion to definite multiple sclerosis. Neurosci Lett 2009; 452(2): 214-7.
14. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G et al. BioMS Study Group, Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009;35(2):117-27.
15. Harris VK,Sadiq SA.Disease biomarkers in multiple sclerosis: Potential for use in therapeutic decision making. Mol Diagn Ther 2009;13(4):225–44.
16. Li W, Zhu S, Li J, Huang Y, Zhou R, Fan X et al. A Hepatic Protein, Fetuin-A, Occupies a Protective Role in Lethal Systemic Inflammation. PLoS ONE 2011; 6(2):e16945,
17. Dziegielewska KM, Matthews N, Saunders NR, Wilkinson G.Alpha 2HS-glycoprotein is expressed at high concentration in human fetal plasma and cerebrospinal fluid. Fetal Diagn Ther 1993;8(1):22–7.
18. Dziegielewska KM, Mollgard K, Reynolds ML, Saunders NR. A fetuin-related glycoprotein (alpha 2HS) in human embryonic and fetal development. Cell Tissue Res. 1987;248(1):33–41.
19. Heinen MC, Babler A, Weis J,Elsas J,Nolte K,Kipp M et al .Fetuin-A protein distribution in mature inflamed and ischemic braintissue. PLoS ONE 2018;13(11):e0206597.
20. Harris VK, Bell L, Langan R-A,Tuddenham J, Landy M, Sadiq SA.Fetuin-A deficiency protects mice from Experimental Autoimmune Encephalomyelitis (EAE) and correlates with altered innate immune respons e.PLoS ONE 2017; 12(4): e0175575.
21. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al.Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology 2018;17(2), 162-73.

APA	Mühürdaroğlu M, eruyar e, KILINCKAYA M, Bilen S, Oztekin N (2023). ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. , 158 - 164.
Chicago	Mühürdaroğlu Mehmet,eruyar esra,KILINCKAYA Muhammed Fevzi,Bilen Sule,Oztekin Nese ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. (2023): 158 - 164.
MLA	Mühürdaroğlu Mehmet,eruyar esra,KILINCKAYA Muhammed Fevzi,Bilen Sule,Oztekin Nese ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. , 2023, ss.158 - 164.
AMA	Mühürdaroğlu M,eruyar e,KILINCKAYA M,Bilen S,Oztekin N ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. . 2023; 158 - 164.
Vancouver	Mühürdaroğlu M,eruyar e,KILINCKAYA M,Bilen S,Oztekin N ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. . 2023; 158 - 164.
IEEE	Mühürdaroğlu M,eruyar e,KILINCKAYA M,Bilen S,Oztekin N "ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS." , ss.158 - 164, 2023.
ISNAD	Mühürdaroğlu, Mehmet vd. "ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS". (2023), 158-164.

APA	Mühürdaroğlu M, eruyar e, KILINCKAYA M, Bilen S, Oztekin N (2023). ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, 27(2), 158 - 164.
Chicago	Mühürdaroğlu Mehmet,eruyar esra,KILINCKAYA Muhammed Fevzi,Bilen Sule,Oztekin Nese ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi 27, no.2 (2023): 158 - 164.
MLA	Mühürdaroğlu Mehmet,eruyar esra,KILINCKAYA Muhammed Fevzi,Bilen Sule,Oztekin Nese ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, vol.27, no.2, 2023, ss.158 - 164.
AMA	Mühürdaroğlu M,eruyar e,KILINCKAYA M,Bilen S,Oztekin N ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2023; 27(2): 158 - 164.
Vancouver	Mühürdaroğlu M,eruyar e,KILINCKAYA M,Bilen S,Oztekin N ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2023; 27(2): 158 - 164.
IEEE	Mühürdaroğlu M,eruyar e,KILINCKAYA M,Bilen S,Oztekin N "ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS." İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, 27, ss.158 - 164, 2023.
ISNAD	Mühürdaroğlu, Mehmet vd. "ASSESSMENT OF DISEASE ACITIVITY IN MULTIPLE SCLEROSIS VIA FETUIN-A LEVELS". İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi 27/2 (2023), 158-164.